GASTROClear
Commercial- Indications
- Gastric cancer
Company intelligence / Profile preview
MiRXES
Singapore, Singaporesg.linkedin.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
MiRXES has developed and commercialized blood-based miRNA test kits for early disease detection, particularly for cancer. Their flagship product GASTROClear is commercially available. Their therapeutic candidate CTX-1 is in preclinical stage for Acute Myeloid Leukemia.
- Therapeutic areas
- OncologyCardiovascularMetabolic DisordersInfectious Diseases
- Modalities
- RNA-based diagnosticsSmall molecule drug
- Industry
- Molecular Diagnostics
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Thermo Fisher ScientificNational University Hospital (NUH)University of Malaya
Beyond the preview
Go deeper on MiRXES.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MiRXES.